233 related articles for article (PubMed ID: 36293924)
41. Beyond Δ9-tetrahydrocannabinol and cannabidiol: chemical differentiation of cannabis varieties applying targeted and untargeted analysis.
Monti MC; Frei P; Weber S; Scheurer E; Mercer-Chalmers-Bender K
Anal Bioanal Chem; 2022 May; 414(13):3847-3862. PubMed ID: 35380230
[TBL] [Abstract][Full Text] [Related]
42. Comparison of hospital claims and poison center data to evaluate health impact of opioids, cannabis and synthetic cannabinoids.
Wang GS; Buttorff C; Wilks A; Schwam D; Tung GJ; Banerji S; Dart RC; Pacula RL
Am J Emerg Med; 2022 Mar; 53():150-153. PubMed ID: 35051702
[TBL] [Abstract][Full Text] [Related]
43. A cross-sectional survey on cannabis: Characterizing motives, opinions, and subjective experiences associated with the use of various oral cannabis products.
Dowd AN; Zamarripa CA; Sholler DJ; Strickland JC; Goffi E; Borodovsky JT; Weerts EM; Vandrey R; Spindle TR
Drug Alcohol Depend; 2023 Apr; 245():109826. PubMed ID: 36871378
[TBL] [Abstract][Full Text] [Related]
44. Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use.
Koch CD; Xu L; Curtis SA; Roberts JD; Bunch DR; El-Khoury JM
Clin Chim Acta; 2020 Nov; 510():515-521. PubMed ID: 32795544
[TBL] [Abstract][Full Text] [Related]
45. Protocol for a mobile laboratory study of co-administration of cannabis concentrates with a standard alcohol dose in humans.
Karoly HC; Prince MA; Emery NN; Smith EE; Piercey CJ; Conner BT
PLoS One; 2022; 17(11):e0277123. PubMed ID: 36327298
[TBL] [Abstract][Full Text] [Related]
46. Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation.
Russo EB; Spooner C; May L; Leslie R; Whiteley VL
Cannabis Cannabinoid Res; 2022 Jun; 7(3):336-344. PubMed ID: 34227878
[No Abstract] [Full Text] [Related]
47. Extensive phytocannabinoid profiles of seized cannabis and cannabis-based medicines - Identification of potential distinguishing markers.
Scheunemann A; Elsner K; Germerott T; Hess C; Zörntlein S; Röhrich J
Forensic Sci Int; 2021 May; 322():110773. PubMed ID: 33839545
[TBL] [Abstract][Full Text] [Related]
48. Investigating sex differences in acute intoxication and verbal memory errors after ad libitum cannabis concentrate use.
Gibson LP; Gust CJ; Ellingson JM; YorkWilliams SL; Sempio C; Klawitter J; Bryan AD; Hutchison KE; Cinnamon Bidwell L
Drug Alcohol Depend; 2021 Jun; 223():108718. PubMed ID: 33866072
[TBL] [Abstract][Full Text] [Related]
49. Trends in cannabis use among adults with children in the home in the United States, 2004-2017: impact of state-level legalization for recreational and medical use.
Goodwin RD; Kim JH; Cheslack-Postava K; Weinberger AH; Wu M; Wyka K; Kattan M
Addiction; 2021 Oct; 116(10):2770-2778. PubMed ID: 33730400
[TBL] [Abstract][Full Text] [Related]
50. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
[TBL] [Abstract][Full Text] [Related]
51. Cannabinoid-Related Acute Pancreatitis: An Update from International Literature and Individual Case Safety Reports.
Azam C; Buscail L; Culetto A; Lapeyre-Mestre M
Drug Saf; 2022 Mar; 45(3):215-235. PubMed ID: 35179705
[TBL] [Abstract][Full Text] [Related]
52. How should policymakers regulate the tetrahydrocannabinol content of cannabis products in a legal market?
Hall W; Leung J; Carlini BH
Addiction; 2023 Jun; 118(6):998-1003. PubMed ID: 36662648
[TBL] [Abstract][Full Text] [Related]
53. 'Synthetic cannabis': A dangerous misnomer.
Darke S; Banister S; Farrell M; Duflou J; Lappin J
Int J Drug Policy; 2021 Dec; 98():103396. PubMed ID: 34343944
[TBL] [Abstract][Full Text] [Related]
54. Danish dog owners' use and the perceived effect of unlicensed cannabis products in dogs.
Holst P; Kristensen AT; Arendt ML
PLoS One; 2024; 19(1):e0296698. PubMed ID: 38295012
[TBL] [Abstract][Full Text] [Related]
55. Long-Term Frequent Cannabis Use and Related Serum Cannabinoid Levels Are Not Associated with Kidney Dysfunction.
Bonnet U; Borda T; Scherbaum N; Specka M
Cannabis Cannabinoid Res; 2022 Oct; 7(5):670-676. PubMed ID: 34704814
[No Abstract] [Full Text] [Related]
56. Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies.
Daldegan-Bueno D; Maia LO; Glass M; Jutras-Aswad D; Fischer B
Eur Neuropsychopharmacol; 2021 Oct; 51():106-131. PubMed ID: 34273801
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence.
Babalonis S; Walsh SL
Eur Neuropsychopharmacol; 2020 Jul; 36():206-216. PubMed ID: 32273144
[TBL] [Abstract][Full Text] [Related]
58. Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores.
Spindle TR; Sholler DJ; Cone EJ; Murphy TP; ElSohly M; Winecker RE; Flegel RR; Bonn-Miller MO; Vandrey R
JAMA Netw Open; 2022 Jul; 5(7):e2223019. PubMed ID: 35857320
[TBL] [Abstract][Full Text] [Related]
59. Estimating the Prevalence of Substance Use Disorders in the US Using the Benchmark Multiplier Method.
Mojtabai R
JAMA Psychiatry; 2022 Nov; 79(11):1074-1080. PubMed ID: 36129721
[TBL] [Abstract][Full Text] [Related]
60. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
